# OnCo record paper-izutsu-ezh1-ezh2-inhibitor-atll-blood-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-izutsu-ezh1-ezh2-inhibitor-atll-blood-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-izutsu-ezh1-ezh2-inhibitor-atll-blood-2023" ;
  schema:name "An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma"@en ;
  schema:alternateName "Izutsu 2023"@en ;
  schema:description "An oral drug blocking the enzymes EZH2 and EZH1 produced responses in 48 per cent of people with relapsed adult T-cell leukaemia/lymphoma, most of whom had already had mogamulizumab."@en ;
  schema:url <https://onco.cc/key-papers/paper-izutsu-ezh1-ezh2-inhibitor-atll-blood-2023/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.1182/blood.2022016862>, <https://pubmed.ncbi.nlm.nih.gov/36150143/>, <https://europepmc.org/article/MED/36150143> ;
  onco:tag "lymphoma-evidence-entities" ;
  schema:sameAs <https://doi.org/10.1182/blood.2022016862> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Izutsu K, Makita S, Nosaka K, et al." ;
  onco:cancers <https://onco.cc/cancers/adult-t-cell-leukaemia-lymphoma/> ;
  onco:targets <https://onco.cc/targets/ezh2/> ;
  onco:trials <https://onco.cc/trials/ds-3201b-atll-phase-2/> .